SEC Form 4 · accession 0001553878-18-000032

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Chief Operating Officer

Period of report

Mar 26, 2018

Accepted (ET)

Mar 28, 2018 · 4:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 26, 2018	M	7,221	$42.22	A	7,221	D
Common Stock^F2	Mar 26, 2018	S	4,308	$136.00	D	2,913	D
Common Stock^F3	Mar 26, 2018	S	2,394	$137.09	D	519	D
Common Stock^F4	Mar 26, 2018	S	419	$137.78	D	100	D
Common Stock	Mar 26, 2018	S	100	$141.47	D	0	D
Common Stock^F5	Mar 26, 2018	J	233	$0.00	A	233	I	by Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$42.22	Mar 26, 2018	M	7,221	D	—	Dec 20, 2026	Common Stock	7,221	17,779	D

F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 17, 2018.
F2Sales prices ranged from $135.53 to $136.51.
F3Sales prices ranged from $136.61 to $137.58.
F4Sales prices ranged from $137.68 to $137.99.
F5Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F6The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.